GLP-1 Weight Loss Drug Pricing Guide: Wegovy, Ozempic, Zepbound Costs in 2026

GLP-1 medications can cost over $16,000 a year without insurance. Here is what each drug actually costs, what programs exist to bring those prices down, and how to find the best deal for your situation.

Why GLP-1 Drug Pricing Is So Complicated

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become some of the most prescribed medications in the United States. Originally developed for type 2 diabetes, these drugs gained massive popularity after clinical trials showed they could help patients lose 15–20% of their body weight.

The pricing for these drugs is anything but straightforward. The amount you pay depends on whether you have insurance, what your plan covers, which indication your doctor prescribes for (diabetes vs. weight management), and whether you qualify for manufacturer assistance programs. Two patients picking up the same drug at the same pharmacy can pay wildly different amounts.

This guide breaks down what each major GLP-1 drug costs in 2026, what savings programs are available, and what alternatives exist if the brand-name price is out of reach.

Brand-Name GLP-1 Drug Prices in 2026

The following prices reflect typical retail costs for a one-month supply without insurance. Actual prices vary by pharmacy and location.

Insurance Coverage: Diabetes vs. Weight Loss

Insurance coverage for GLP-1 drugs depends heavily on the reason for the prescription. Most commercial insurance plans and Medicare Part D cover Ozempic and Mounjaro when prescribed for type 2 diabetes, though copays and prior authorization requirements vary.

Coverage for weight management is a different story. Many insurance plans explicitly exclude weight-loss medications. Even when plans do cover Wegovy or Zepbound for obesity, they often impose strict requirements:

• Prior authorization with documented BMI of 30+ (or 27+ with a weight-related condition)
• Evidence of failed attempts with diet and exercise
• Step therapy requiring you to try cheaper medications first
• Quantity limits or annual coverage caps

Medicare Part D began covering some anti-obesity medications in 2026 for patients with established cardiovascular disease, following the TREAT Act provisions. However, coverage remains limited, and many Medicare beneficiaries still face significant out-of-pocket costs.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer programs designed to reduce the cost for eligible patients. These programs change frequently, so verify current terms directly with each manufacturer.

Novo Nordisk (Wegovy, Ozempic)

Novo Nordisk offers a self-pay program for Wegovy that brings the monthly cost down to approximately $499 per month for patients who pay entirely out of pocket without using insurance. The company also runs savings cards for commercially insured patients that can reduce copays, though patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for these cards.

Eli Lilly (Zepbound, Mounjaro)

Eli Lilly has been more aggressive on pricing. Through its LillyDirect platform, the company sells Zepbound single-dose vials directly to patients at $299 to $449 per month, depending on the dose. These vials require drawing the medication into a syringe, which some patients may find less convenient than pre-filled pens.

In February 2026, Lilly introduced the Zepbound KwikPen — a pre-filled, disposable injection device — available through LillyDirect at $299 to $449 per month depending on the dose level. This device offers the same convenience as a standard auto-injector pen without requiring patients to handle vials and syringes.

Compounded Semaglutide: Lower Cost, Important Caveats

Compounded semaglutide has emerged as a lower-cost alternative, typically priced between $200 and $400 per month through telehealth platforms and compounding pharmacies. But it comes with important caveats that every patient should understand.

Compounding pharmacies create custom preparations of medications. During a period when Ozempic and Wegovy faced supply shortages, the FDA allowed compounding pharmacies to produce semaglutide under its shortage provisions. Compounded versions are not FDA-approved products — they have not gone through the same manufacturing, testing, and quality control processes as brand-name drugs.

The FDA has raised concerns about compounded semaglutide, including:

• Inconsistent dosing between batches
• Use of semaglutide salt forms (such as semaglutide sodium) that differ from the approved product
• Sterility risks at some compounding facilities
• Lack of long-term safety data for compounded formulations

As brand-name supply has stabilized, the FDA has moved to restrict compounded semaglutide production. The legal and regulatory landscape around compounded GLP-1 drugs continues to shift, and availability may change. If you are considering a compounded product, verify that the pharmacy is registered with the FDA and accredited by the Pharmacy Compounding Accreditation Board (PCAB) or a similar body.

Practical Tips to Reduce Your GLP-1 Costs

Regardless of which drug you take, these strategies can help lower what you pay:

1. Compare prices across pharmacies. GLP-1 prices vary significantly between retail pharmacies, mail-order pharmacies, and direct-to-patient programs. Use a tool like RxGator to compare prices from multiple sources before filling your prescription.
2. Ask about manufacturer programs first. Contact Novo Nordisk (for Wegovy/Ozempic) or Eli Lilly (for Zepbound/Mounjaro) directly. Eligibility requirements and pricing change, and phone representatives can walk you through current options.
3. Consider the LillyDirect route. If you are open to tirzepatide, Eli Lilly’s direct-to-patient vials and KwikPens at $299–$449/month represent some of the lowest brand-name GLP-1 pricing available.
4. Appeal insurance denials. If your insurer denies coverage, ask your doctor to submit a prior authorization or a letter of medical necessity. Many denials are overturned on appeal, especially when documentation of BMI, comorbidities, and failed alternatives is thorough.
5. Check employer benefits. Some large employers have added GLP-1 coverage as a specific benefit. Ask your HR department whether your plan covers weight-management medications, even if the general formulary does not list them.
6. Review patient assistance programs. Both manufacturers offer programs for patients who meet income thresholds. NeedyMeds and RxAssist maintain updated directories of pharmaceutical assistance programs.
7. Stay on the lowest effective dose. Higher doses cost more through programs like LillyDirect. Work with your doctor to determine whether a lower maintenance dose provides adequate results for your situation.

The Bottom Line

GLP-1 medications remain expensive, but the pricing landscape has improved since these drugs first launched. Manufacturer direct-to-patient programs — particularly Eli Lilly’s LillyDirect offerings — have brought monthly costs below $500 for some patients. Insurance coverage continues to expand, and legislative efforts to broaden Medicare coverage are ongoing.

The single most important step you can take is to compare prices before filling your prescription. The difference between the highest and lowest available price for the same drug can be hundreds of dollars per month.